Skip to main content
U.S. flag

An official website of the United States government

Division Announcements

4th Annual NIA-AA Symposium: Enabling Precision Medicine for AD Through Open Science

October 27 – 28, 2021
10:00am – 3:00pm EDT

Purpose and Background

This live, virtual symposium will feature an array of NIA-supported translational research programs that employ precision medicine principles and open-science practices to:

  1. Understand the complex and heterogeneous etiology of Alzheimer’s
  2. Identify new disease-relevant targets and biomarkers
  3. Develop the next generation animal models for late onset AD and,
  4. Advance novel targets into drug discovery by developing target enabling research tools.

The symposium program will feature scientific advances and translational infrastructure resources developed by the: Accelerating Medicines Partnership® for Alzheimer’s Disease (AMP AD), the Alzheimer’s Gut Microbiome Project (AGMP), MODEL- AD Consortium, TREAT- AD Centers, the Alzheimer’s Biomarkers Consortium - Down Syndrome (ABC-DS) and other consortia.


While all are welcome, this symposium is designed for academic, biotech and pharmaceutical industry researchers with an interest in target and biomarker discovery, preclinical and clinical drug development. Other groups who may be interested include computational biologists, data scientists, and open science advocates.


Use this link to register for this free symposium.


Day 1 (Wednesday, October 27)

10:00am – 11:30am: Session 1 | AMP AD: Precision Medicine Approach to Novel Target and Biomarker Discovery

Co-Chairs: Nilüfer Ertekin-Taner, Mayo Clinic and Matthias Arnold, Helmholtz University


  • Bin Zhang, Icahn School of Medicine at Mount Sinai
  • Laura Heath, Sage Bionetworks
  • Phil De Jager, Columbia University
  • Lenora Ann Higginbotham, Emory University

11:10am – 11:30am: Session 1 Q&A

11:30am – 11:45am: Break

11:45am – 1:15pm: Session 2 | MODEL-AD Consortium: A Precision Medicine Approach to the Development of Animal Models of Late Onset AD and Preclinical Efficacy Testing

Co-Chairs: Bruce Lamb, Indiana University and Andrea Tenner, University of California, Irvine


  • Greg Carter, The Jackson Laboratory
  • Gareth Howell, The Jackson Laboratory
  • Adrian Oblak, Indiana University
  • Paul Territo, Indiana University
  • Stacey Rizzo, University of Pittsburgh
  • Ali Mortazavi, University of California, Irvine
  • Kim Green, University of California, Irvine

12:55pm – 1:15pm Session 2 Q&A

1:15pm – 1:30pm Break

1:30pm – 3:00pm: Session 3 | TREAT-AD Centers: Expanding the AD Target Landscape and Accelerating Drug Discovery for Novel Targets

Co-Chairs: Alan Palkowitz, Indiana University and Lara Mangravite, Sage Bionetworks


  • Timothy Richardson, Indiana University
  • Andrew Mesecar, Indian University
  • Lara Mangravite, Sage Bionetworks
  • Nick Seyfried Emory University
  • Haian Fu, Emory University

2:40pm – 3:00pm: Session 3 Q&A

Day 2 (Thursday, October 28)

10:00am – 11:30am: Session 4 | Alzheimer’s Gut Microbiome Project

Co-Chairs: Rima Kaddurah-Daouk, Duke University and Sarkis Mazmanian, California Institute of Technology


  • Rob Knight, University of California, San Diego
  • Sarkis Mazmanian, California Institute of Technology
  • Gabi Kastenmüller, Helmholtz University

11:10am – 11:30am: Session 4 Q&A

11:30pm – 11:45pm: Break

11:45am – 1:15pm: Session 5 | Impact of Sex Differences on the Molecular Determinants of AD Risk and Resilience and Responsiveness to Treatment

Co-Chairs: Catherine Kaczorowski, The Jackson Laboratory and Susan Catalano, Cognition Therapeutics


  • Ivan Nalvarte, Karolinska Institute
  • Carol Colton, Duke University
  • Marina Sirota, University of California San Francisco
  • Dena Dubal, University of California San Francisco

12:55pm – 1:15pm: Session 5 Q&A

1:15pm – 1:30pm: Break

1:30pm – 3:00pm: Session 6 | Precision Medicine Cohorts and Consortia: ABC-DS, HABS-HD, LEADS

Co-Chairs: Sid O’Bryant, University of North Texas Health Science Center and Liana Apostolova, Indiana University


  • Liz Head, University of California, Irvine
  • Annie Cohen, University of Pittsburgh
  • Mark Mapstone, University of California, Irvine
  • Sid O’Bryant, University of North Texas Health Science Center
  • Liana Apostolova, Indiana University

2:40pm – 3:00pm: Session 6 Q&A

An official website of the National Institutes of Health